NASDAQ:ZLAB - Zai Lab Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $117.50
  • Forecasted Upside: 183.75 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$41.41
▲ +2.87 (7.45%)

This chart shows the closing price for ZLAB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Zai Lab Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ZLAB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ZLAB

Analyst Price Target is $117.50
▲ +183.75% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Zai Lab in the last 3 months. The average price target is $117.50, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 183.75% upside from the last price of $41.41.

This chart shows the closing price for ZLAB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 polled investment analysts is to buy stock in Zai Lab. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/11/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/11/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/10/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/8/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/6/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/6/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/5/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/5/2022

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/12/2022CitigroupLower Price Target$198.00 ➝ $193.00High
4/21/2022SVB LeerinkLower Price TargetOutperform$102.00 ➝ $101.00High
4/4/2022JPMorgan Chase & Co.Lower Price TargetOverweight$136.00 ➝ $112.00High
3/2/2022SVB LeerinkLower Price TargetOutperform$194.00 ➝ $102.00High
1/21/2022MacquarieInitiated CoverageOutperform$64.00High
12/15/2021JPMorgan Chase & Co.Lower Price TargetOverweight$189.00 ➝ $136.00High
12/12/2021SVB LeerinkReiterated RatingBuyMedium
12/3/2021CitigroupBoost Price TargetBuy ➝ Buy$217.00 ➝ $231.00Low
11/11/2021CitigroupLower Price TargetBuy$222.00 ➝ $217.00Low
11/10/2021SVB LeerinkLower Price TargetOutperform$200.00 ➝ $194.00Medium
10/12/2021Sanford C. BernsteinInitiated CoverageMarket PerformHigh
6/1/2021SVB LeerinkBoost Price TargetOutperform$192.00 ➝ $202.00Medium
4/14/2021SVB LeerinkBoost Price TargetOutperform$183.00 ➝ $192.00Low
4/13/2021The Goldman Sachs GroupBoost Price TargetBuy$205.73 ➝ $211.23Medium
4/13/2021GuggenheimBoost Price Target$165.00 ➝ $250.00High
2/8/2021Jefferies Financial GroupBoost Price TargetBuy$130.00 ➝ $225.00Medium
2/3/2021SVB LeerinkBoost Price TargetOutperform$107.00 ➝ $189.00Low
11/16/2020JPMorgan Chase & Co.Boost Price Target$101.00 ➝ $111.00Low
11/3/2020JPMorgan Chase & Co.Boost Price TargetOverweight$65.00 ➝ $101.00Medium
9/10/2020SVB LeerinkBoost Price TargetOutperform$93.00 ➝ $95.00High
8/14/2020GuggenheimBoost Price TargetPositive ➝ Buy$105.00 ➝ $111.00Medium
7/8/2020GuggenheimBoost Price TargetBuy$75.00 ➝ $105.00High
7/7/2020SVB LeerinkBoost Price TargetOutperform$79.00 ➝ $93.00Low
4/27/2020The Goldman Sachs GroupInitiated CoverageBuyMedium
4/15/2020GuggenheimInitiated CoverageBuy$75.00Low
12/30/2019CitigroupBoost Price TargetBuy$65.00 ➝ $84.00Low
9/4/2019CitigroupSet Price TargetBuy$65.00Low
9/4/2019SVB LeerinkSet Price TargetBuy$48.00Low
7/15/2019SVB LeerinkSet Price TargetBuy$47.00Low
7/12/2019Bank of AmericaInitiated CoverageBuy ➝ Buy$43.00Medium
7/5/2019MacquarieInitiated CoverageOutperform ➝ Outperform$36.54Low
6/11/2019SVB LeerinkSet Price TargetBuy$46.00Medium
1/29/2019Credit Suisse GroupInitiated CoverageOutperform$34.70High
11/21/2018Jefferies Financial GroupInitiated CoverageBuy ➝ BuyLow
6/28/2018SVB LeerinkReiterated RatingOutperform$43.00Medium
6/21/2018SVB LeerinkInitiated CoverageOutperform$43.00Medium
3/23/2018SVB LeerinkReiterated RatingOutperformLow
2/14/2018JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$32.00High
10/16/2017SVB LeerinkInitiated CoverageOutperform ➝ Outperform$42.00N/A
10/16/2017CitigroupInitiated CoverageBuyN/A
10/16/2017JPMorgan Chase & Co.Initiated CoverageNeutral ➝ Neutral$32.00N/A
(Data available from 7/5/2017 forward)

News Sentiment Rating

0.42 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 9 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/7/2021
  • 3 very positive mentions
  • 4 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
1/6/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 3 very negative mentions
2/5/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
3/7/2022
  • 4 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
4/6/2022
  • 3 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
5/6/2022
  • 1 very positive mentions
  • 10 positive mentions
  • 3 negative mentions
  • 3 very negative mentions
6/5/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/5/2022

Current Sentiment

  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Zai Lab logo
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.
Read More

Today's Range

Now: $41.41
Low: $38.21
High: $42.74

50 Day Range

MA: $32.04
Low: $23.14
High: $42.77

52 Week Range

Now: $41.41
Low: $22.51
High: $176.17

Volume

1,387,145 shs

Average Volume

775,094 shs

Market Capitalization

$4.05 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.02

Frequently Asked Questions

What sell-side analysts currently cover shares of Zai Lab?

The following equities research analysts have issued reports on Zai Lab in the last twelve months: Citigroup Inc., JPMorgan Chase & Co., Macquarie, Sanford C. Bernstein, and SVB Leerink LLC.
View the latest analyst ratings for ZLAB.

What is the current price target for Zai Lab?

0 Wall Street analysts have set twelve-month price targets for Zai Lab in the last year. Their average twelve-month price target is $117.50, suggesting a possible upside of 183.7%.
View the latest price targets for ZLAB.

What is the current consensus analyst rating for Zai Lab?

Zai Lab currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ZLAB will outperform the market and that investors should add to their positions of Zai Lab.
View the latest ratings for ZLAB.

How do I contact Zai Lab's investor relations team?

Zai Lab's physical mailing address is 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210. The company's listed phone number is 862161632588 and its investor relations email address is [email protected] The official website for Zai Lab is www.zailaboratory.com. Learn More about contacing Zai Lab investor relations.